Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implications for future pricing considerations
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | https://doi.org/10.3389/fphar.2017.00041 http://hdl.handle.net/1843/59596 |
Resumo: | Introduction and objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil’s regulatory chamber of pharmaceutical products market for the commercialization of Dengvaxia® for three doses, only 17% of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population. |
id |
UFMG_fc71126af62f79a0daab088ddffe9091 |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/59596 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
2023-10-18T14:55:43Z2023-10-18T14:55:43Z2017819https://doi.org/10.3389/fphar.2017.000411663-9812http://hdl.handle.net/1843/59596Introduction and objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil’s regulatory chamber of pharmaceutical products market for the commercialization of Dengvaxia® for three doses, only 17% of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.Introdução e objetivo: O vírus da dengue é um grave problema de saúde global, com cerca de 3,97 bilhões de pessoas em risco de infecção em todo o mundo. Em dezembro de 2015, foi aprovada no Brasil a primeira vacina (CYD-TDV) para prevenção da dengue, desenvolvida pela Sanofi Pasteur. No entanto, dado que a vacina será potencialmente paga através do sistema público de saúde, são necessárias informações sobre a disposição dos consumidores em pagar pela vacina contra a dengue no país, bem como discussões relacionadas com a possível inclusão desta vacina no sistema público de saúde. Este foi o objetivo desta pesquisa. Métodos: Realizamos um estudo transversal com moradores da Grande Belo Horizonte, Minas Gerais, sobre sua disposição de pagar pela vacina CYD-TDV. Resultados: foram entrevistados 507 indivíduos. A maioria era do sexo feminino (62,4%), tinha ensino médio completo (62,17%), trabalhava (74,4%), possuía plano de saúde privado (64,5%) e não tinha dengue (67,4%). O valor mediano máximo da disposição dos consumidores a pagar pela vacina CYD-TDV é de US$ 33,61 (120,00 BRL) para o esquema completo e US$ 11,20 (40,00 BRL) por dose. Ao preço determinado pela Câmara Reguladora do Mercado de Produtos Farmacêuticos do Brasil para a comercialização de três doses da Dengvaxia®, apenas 17% da população se manifestou disposta a pagar por esta vacina. Conclusão: O Brasil é atualmente um dos maiores mercados para a vacina contra dengue e o preço estabelecido é uma questão fundamental. Acreditamos que a fabricante deva avaliar a possibilidade de preços mais baixos para atingir um público maior entre a população brasileira.CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorengUniversidade Federal de Minas GeraisUFMGBrasilFAR - DEPARTAMENTO DE FARMÁCIA SOCIALICX - DEPARTAMENTO DE ESTATÍSTICAFrontiers in PharmacologyDengueVacinasComportamento do consumidorBrasilDengueWillingness to payVaccineConsumersBrazilConsumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implications for future pricing considerationsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleIsabella Piassi Dias GodóiAndré Soares SantosEdna Afonso ReisLivia Lovato Pires de LemosCristina Mariano Ruas BrandãoJuliana Alvares TeodoroFrancisco de Assis AcurcioBrian GodmanAugusto Afonso Guerra Júniorapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/59596/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALConsumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil implications for future pricing considerations.pdfConsumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil implications for future pricing considerations.pdfapplication/pdf574792https://repositorio.ufmg.br/bitstream/1843/59596/2/Consumer%20willingness%20to%20pay%20for%20dengue%20vaccine%20%28CYD-TDV%2c%20Dengvaxia%c2%ae%29%20in%20Brazil%20implications%20for%20future%20pricing%20considerations.pdfdbc80345e6009caecd6149ac89fcc177MD521843/595962023-10-18 17:28:29.474oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-10-18T20:28:29Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.pt_BR.fl_str_mv |
Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implications for future pricing considerations |
title |
Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implications for future pricing considerations |
spellingShingle |
Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implications for future pricing considerations Isabella Piassi Dias Godói Dengue Willingness to pay Vaccine Consumers Brazil Dengue Vacinas Comportamento do consumidor Brasil |
title_short |
Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implications for future pricing considerations |
title_full |
Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implications for future pricing considerations |
title_fullStr |
Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implications for future pricing considerations |
title_full_unstemmed |
Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implications for future pricing considerations |
title_sort |
Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implications for future pricing considerations |
author |
Isabella Piassi Dias Godói |
author_facet |
Isabella Piassi Dias Godói André Soares Santos Edna Afonso Reis Livia Lovato Pires de Lemos Cristina Mariano Ruas Brandão Juliana Alvares Teodoro Francisco de Assis Acurcio Brian Godman Augusto Afonso Guerra Júnior |
author_role |
author |
author2 |
André Soares Santos Edna Afonso Reis Livia Lovato Pires de Lemos Cristina Mariano Ruas Brandão Juliana Alvares Teodoro Francisco de Assis Acurcio Brian Godman Augusto Afonso Guerra Júnior |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Isabella Piassi Dias Godói André Soares Santos Edna Afonso Reis Livia Lovato Pires de Lemos Cristina Mariano Ruas Brandão Juliana Alvares Teodoro Francisco de Assis Acurcio Brian Godman Augusto Afonso Guerra Júnior |
dc.subject.por.fl_str_mv |
Dengue Willingness to pay Vaccine Consumers Brazil |
topic |
Dengue Willingness to pay Vaccine Consumers Brazil Dengue Vacinas Comportamento do consumidor Brasil |
dc.subject.other.pt_BR.fl_str_mv |
Dengue Vacinas Comportamento do consumidor Brasil |
description |
Introduction and objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil’s regulatory chamber of pharmaceutical products market for the commercialization of Dengvaxia® for three doses, only 17% of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population. |
publishDate |
2017 |
dc.date.issued.fl_str_mv |
2017 |
dc.date.accessioned.fl_str_mv |
2023-10-18T14:55:43Z |
dc.date.available.fl_str_mv |
2023-10-18T14:55:43Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/59596 |
dc.identifier.doi.pt_BR.fl_str_mv |
https://doi.org/10.3389/fphar.2017.00041 |
dc.identifier.issn.pt_BR.fl_str_mv |
1663-9812 |
url |
https://doi.org/10.3389/fphar.2017.00041 http://hdl.handle.net/1843/59596 |
identifier_str_mv |
1663-9812 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Frontiers in Pharmacology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.publisher.initials.fl_str_mv |
UFMG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
FAR - DEPARTAMENTO DE FARMÁCIA SOCIAL ICX - DEPARTAMENTO DE ESTATÍSTICA |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/59596/1/License.txt https://repositorio.ufmg.br/bitstream/1843/59596/2/Consumer%20willingness%20to%20pay%20for%20dengue%20vaccine%20%28CYD-TDV%2c%20Dengvaxia%c2%ae%29%20in%20Brazil%20implications%20for%20future%20pricing%20considerations.pdf |
bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 dbc80345e6009caecd6149ac89fcc177 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
|
_version_ |
1801676823743954944 |